Cumberland Partners Ltd Acquires 53,970 Shares of Pfizer Inc. $PFE

Key Points

• Cumberland Partners Ltd increased its Pfizer stake by 70.5% in the fourth quarter, adding 53,970 shares to reach 130,570 shares worth about $3.25 million.
• Pfizer’s pipeline news was mixed but leaned positive, with progress in its Phase 3 Lyme vaccine trial and broader pneumococcal vaccine efforts, while an early KRAS cancer trial was terminated.
• The company recently beat quarterly earnings and revenue estimates, and it continues to offer a sizable dividend, with a 6.6% yield based on the announced $0.43 quarterly payout.

Cumberland Partners Ltd boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 70.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 130,570 shares of the biopharmaceutical company's stock after buying an additional 53,970 shares during the period. Cumberland Partners Ltd's holdings in Pfizer were worth $3,251,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Nixon Peabody Trust Co. bought a new position in Pfizer in the 4th quarter worth approximately $203,000. Legato Capital Management LLC bought a new position in Pfizer in the 4th quarter worth approximately $2,707,000. LSV Asset Management increased its position in Pfizer by 3.4% in the 4th quarter. LSV Asset Management now owns 17,502,714 shares of the biopharmaceutical company's stock worth $435,818,000 after buying an additional 579,377 shares during the period. Advisory Alpha LLC increased its position in Pfizer by 5.3% in the 4th quarter. Advisory Alpha LLC now owns 41,790 shares of the biopharmaceutical company's stock worth $1,041,000 after buying an additional 2,122 shares during the period. Finally, SGL Investment Advisors Inc. bought a new position in Pfizer in the 4th quarter worth approximately $385,000. 68.36% of the stock is owned by institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
• Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
• Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
• Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
• Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
• Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.92 on Friday. Pfizer Inc. has a 1-year low of $22.88 and a 1-year high of $28.75. The firm has a market capitalization of $147.72 billion, a PE ratio of 19.79 and a beta of 0.35. The business's 50 day moving average is $26.86 and its 200-day moving average is $26.23. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer's payout ratio is currently 131.30%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFE. HSBC lifted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Tuesday, March 17th. UBS Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Monday, April 13th. Guggenheim lifted their price objective on Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Finally, Morgan Stanley lifted their price objective on Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $28.61.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.